Published in Front Endocrinol (Lausanne) on July 18, 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. Epigenetics (2013) 0.89
Molecular signatures in urologic tumors. Int J Mol Sci (2013) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Immunologic basis of vaccine vectors. Immunity (2010) 1.71
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs (2010) 1.23
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs (2008) 1.08
When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer (2008) 1.07
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol (2008) 1.05
Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother (2008) 1.03
Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines (2008) 0.97
Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer (2009) 0.95
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Differential proteomic alterations between localised and metastatic prostate cancer. Br J Cancer (2006) 0.90
Growth regulatory factors and bone. Rev Endocr Metab Disord (2001) 0.89
Control of prostate growth. Urology (1981) 0.87
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.87
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer (2007) 1.58
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest (2009) 1.51
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer (2006) 1.47
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol (2006) 1.45
Effects of media information on cancer patients' opinions, feelings, decision-making process and physician-patient communication. Cancer (2004) 1.45
Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res (2006) 1.33
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat (2007) 1.30
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology (2005) 1.15
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) (2003) 1.14
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer (2009) 1.13
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol (2006) 1.06
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer (2004) 1.04
Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer (2006) 1.04
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology (2009) 1.02
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res (2010) 1.00
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer (2008) 0.99
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology (2005) 0.98
Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer (2008) 0.97
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res (2011) 0.96
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol (2003) 0.95
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer (2005) 0.94
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer (2010) 0.94
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol (2007) 0.93
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol (2003) 0.93
Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma. Cancer Lett (2005) 0.91
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther (2008) 0.88
Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer (2008) 0.87
Bone metastasis from glioblastoma multiforme without central nervous system relapse: a case report. Anticancer Res (2004) 0.85
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol (2005) 0.85
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol (2006) 0.84
Targeting targeted agents: open issues for clinical trial design. J Exp Clin Cancer Res (2009) 0.83
Zoledronic acid and angiogenesis. Clin Cancer Res (2007) 0.83
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study. Anticancer Res (2004) 0.81
Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. Anticancer Res (2008) 0.81
Genetic profile identification in clinically localized prostate carcinoma. Urol Oncol (2008) 0.79
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest (2006) 0.78
Docetaxel in advanced gastric cancer--review of the main clinical trials. Acta Oncol (2003) 0.78
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study. Cancer Chemother Pharmacol (2005) 0.78
Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients. Cancer Invest (2004) 0.77
Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. Future Oncol (2013) 0.76
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rev (2006) 0.76
Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery. Head Neck (2005) 0.76
Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer. Oncologist (2006) 0.76
Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology (2005) 0.76
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality? J Clin Oncol (2005) 0.76
Early recurrence risk: aromatase inhibitors versus tamoxifen. Expert Rev Anticancer Ther (2010) 0.76
What is the biological significance of circulating blood levels of metalloproteinases? Clin Cancer Res (2006) 0.75
Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial. J Natl Cancer Inst (2007) 0.75
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer. Oncologist (2006) 0.75
Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst (2002) 0.75
Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer. Breast Cancer Res Treat (2005) 0.75
Exemestane or tamoxifen? Lancet (2007) 0.75
Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial. J Natl Cancer Inst (2007) 0.75
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear? J Clin Oncol (2004) 0.75
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst (2007) 0.75
Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer? Breast (2005) 0.75
[Capecitabine in the treatment of colorectal cancer]. Tumori (2001) 0.75
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. Bone (2007) 0.75
Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res (2005) 0.75
Self-monitoring versus standard monitoring of oral anticoagulation. Thromb Res (2006) 0.75
Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. Thromb Res (2006) 0.75
Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. Anticancer Drugs (2017) 0.75
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer. Am J Clin Oncol (2002) 0.75